1. Home
  2. PTEN vs ACAD Comparison

PTEN vs ACAD Comparison

Compare PTEN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Patterson-UTI Energy Inc.

PTEN

Patterson-UTI Energy Inc.

HOLD

Current Price

$12.26

Market Cap

4.1B

Sector

Energy

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.09

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTEN
ACAD
Founded
1978
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
3.8B
IPO Year
1995
2000

Fundamental Metrics

Financial Performance
Metric
PTEN
ACAD
Price
$12.26
$21.09
Analyst Decision
Buy
Buy
Analyst Count
10
22
Target Price
$10.80
$30.55
AVG Volume (30 Days)
7.7M
1.6M
Earning Date
04-22-2026
05-06-2026
Dividend Yield
3.24%
N/A
EPS Growth
90.16
69.12
EPS
N/A
0.02
Revenue
$4,826,624,000.00
$726,437,000.00
Revenue This Year
N/A
$18.80
Revenue Next Year
$4.34
$11.70
P/E Ratio
N/A
$1,066.50
Revenue Growth
N/A
40.45
52 Week Low
$5.10
$19.69
52 Week High
$13.08
$28.35

Technical Indicators

Market Signals
Indicator
PTEN
ACAD
Relative Strength Index (RSI) 57.21 44.59
Support Level $5.31 $20.06
Resistance Level $12.62 $22.64
Average True Range (ATR) 0.52 0.80
MACD -0.03 -0.10
Stochastic Oscillator 57.75 29.60

Price Performance

Historical Comparison
PTEN
ACAD

About PTEN Patterson-UTI Energy Inc.

Patterson-UTI Energy Inc is a Texas based provider of drilling and completion services to oil and natural gas exploration and production companies, offering contract drilling, integrated well completion, directional drilling services, and specialized drill bit solutions. The Company operates through three segments: Drilling Services, Completion Services, and Drilling Products. Drilling Services includes contract and directional drilling, Completion Services generates maximum revenue and includes hydraulic fracturing and related support services, and Drilling Products includes the manufacturing and distribution of drill bits. The Company operates in the United States, Canada, Colombia, and Other Countries, with the majority of revenue coming from the United States.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: